Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 20;14(4):99235. doi: 10.5493/wjem.v14.i4.99235

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

PMC Copyright notice

Ranibizumab remains the first-line agent and the standard of care in the management of diabetic macular edema. A: Fundus photograph of the right eye of a patient with moderate non-proliferative diabetic retinopathy shows retinal thickening and hard exudates (arrow) suggestive of clinically significant macular edema (CSME); B: Corresponding swept source optical coherence tomography scan shows intraretinal (arrow-head) and subretinal fluid (asterisk) along with hard exudates (arrow); C and D: Treatment with Intravitreal Ranibizumab (Accentrix^®) resulted in resolution of CSME and improvement in visual acuity from 6/18 to 6/9.